Clinical trial · no report yet · Phase 3
EMBER-4
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
- NCT05514054 ↗
- Active, not recruiting
- Eli Lilly and Company
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 25 | |
| Podcasts | 22 | |
| X threads | 8 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Neoplasms
- Interventions
- Imlunestrant; Tamoxifen; Anastrozole; Letrozole; Exemestane
- Arms
- Imlunestrant · Experimental
- Investigator's Choice of Endocrine Therapy · Active comparator
- Enrollment
- 8,000 (estimated)
- Primary outcomes
- Invasive Disease-Free Survival (IDFS)
- Sponsor
- Eli Lilly and Company
- Start
- Oct 4, 2022
- Primary completion
- Oct 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05514054 · updated Apr 2, 2026